Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719455 | 0.87 | MEN1 (0.55) | MEN1KMT2ANLRP3ADORA3RAB9A | |
| SCHEMBL717894 | 0.85 | MEN1 (0.50) | MEN1KMT2ANLRP3ADORA3RAB9A | |
| SCHEMBL124130 | 0.82 | PTGS2 (0.58) | MEN1KMT2ANLRP3ADORA3RAB9A | |
| SCHEMBL718901 | 0.81 | MEN1 (0.60) | MEN1KMT2ANLRP3ADORA3RAB9A | |
| SCHEMBL724099 | 0.79 | SMN1; SMN2 (0.50) | MEN1KMT2ANLRP3ALDH1A1 | |
| SCHEMBL719698 | 0.79 | PTGS2 (0.40) | MEN1KMT2ANLRP3ADORA3RAB9A | |
| SCHEMBL23400147 | 0.78 | RAB9A (0.52) | MEN1KMT2AADORA3RAB9AL3MBTL1 | |
| SCHEMBL719988 | 0.77 | MEN1 (0.56) | MEN1KMT2ANLRP3ADORA3RAB9A | |
| SCHEMBL719353 | 0.77 | NOTUM (0.48) | MEN1KMT2ANLRP3ALDH1A1PTGS2 | |
| SCHEMBL2555928 | 0.76 | MEN1 (0.59) | MEN1KMT2ANLRP3ADORA3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MEN1 444/4885KMT2A 1298/4885NLRP3 1630/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MEN1 444/4885KMT2A 1298/4885NLRP3 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.